• ChromoTek GmbH
  • Am Klopferspitz 19
  • 82152 Planegg/Martinsried
  • Germany
  • Phone: +49 (0)89/12 41 48 80
  • Fax: +49 (0)89 12 41 48 811
  • moc.ketomorhc@ofni

ChromoTek

Dr. Marion Jung
Geschäftsführerin / Managing Director

About ChromoTek

ChromoTek is a pioneer in the development and commercialization of innovative reagents based on camelid Nanobodies. In contrast to traditional antibodies, nanobodies consist of only one single polypeptide chain; they are the smallest known antibodies. The company has a unique experience in the development of nanobodies with desired affinities, specificities, and formats for dedicated applications in biomedical research where other antibody formats fail. As a market and product leader for high performing reagents, we are proudly contributing to breakthrough research discoveries around the world. In October 2020 ChromoTek was acquired by Proteintech Group. The combined companies will better address the industry’s growing opportunities. Founded in 2008, ChromoTek continues to grow its business in Martinsried.

What ist your motivation?

A creative mindset, the passion for science and the belief in innovation as a motor for the greater good make me tick. I like to challenge traditional approaches. Hence, I am attracted to proceed applying less conventional methods and yet taking advantage of learning and observing from others. No one has ever accomplished before, what the scientific founding team of ChromoTek has realized. I want to keep their vision alive and I am proud how  far we have come; however, the next challenges are already waiting. It is a rare privilege to have such a creative working environment with a team that gets energized the more difficult the resolution of a problem seems to be. Above all, there is the desire to contribute with our work to the long and risky value chain that ultimately improves our health.

“From the IZB into the world – serving scientists in more than 50 countries.”

Dr. Marion Jung
Geschäftsführerin / Managing Director

ChromoTek GmbH, founded in 2008, is a biotech company focused on the discovery and development of novel nanoprobes and cell based assays for biomedical research and early drug development. During the last years ChromoTek has developed innovative research tools including the GFP-Trap® and RFP-Trap®, two versatile pull-down reagents for biochemical analysis of fluorescent fusion proteins. In April 2011 ChromoTek successfully introduced its first cell based assay for early drug development, the U2OS Cell Cycle Chromobody®. This real-time High-Content Analysis (HCA) screening assay enables to monitor the complete cell cycle in live cells for the first time. In addition ChromoTek developed the Fluorescent 2-Hybrid (F2H)-Assay to analyze protein-protein interactions in vivo in real time.